“Researchers at the University of South Florida (USF) have identified a bacterium in Antarctic sea squirts that selectively kills melanoma cells without harming healthy human cells, marking a potential breakthrough in cancer treatment, according to multiple sources. The discovery, made during a six-week expedition to Antarctica, involves a compound produced by the bacterium Candidatus Synoicihabitans palmerolidicus that could advance drug development for the deadliest form of skin cancer.”
The Antarctic Expedition and Its Challenges
The Antarctic Expedition and Its Challenges
The research team, led by USF professor Brian Baker, conducted dives to depths of up to 130 feet in icy Antarctic waters, facing extreme conditions including leopard seals, shifting sea ice, and limited visibility. "In Antarctica, you’re dealing with ice, leopard seals, changing seas and sometimes very limited visibility," said Ben Meister, a USF professor who oversaw the expedition funded by the National Science Foundation. The team collected ascidians—marine invertebrates known as sea squirts—that harbor the bacterium. "Every dive must be carefully planned to balance getting the work done while keeping everyone safe," Meister added.
The Medical Potential of the Discovery
The Medical Potential of the Discovery
The bacterium’s compound, palmerolide A, demonstrated "selectivity" in targeting melanoma cells, a critical factor in drug development. "That selectivity is critical in drug development because you want to treat the disease without harming the patient," said Bill Baker, a USF chemistry professor co-leading the research. In mouse trials, the compound killed cancer cells without harming the animals, though researchers emphasize the path to a human drug is long. "We need grams of material to do a bigger study in mice," Baker said. The team now aims to synthetically reproduce the toxin in labs, as collecting large quantities from the Antarctic ecosystem would be ecologically unsustainable.
Unique Angles from Each Source
Unique Angles from Each Source
The Guardian highlighted the logistical challenges of the expedition, noting the team’s exhaustion upon return but excitement about lab work. Science Focus emphasized the broader significance of the discovery, comparing it to other extremophile organisms like naked mole-rats and scorpion venom. Yahoo.com provided detailed biological context, explaining how Antarctica’s isolation over millions of years led to the evolution of specialized species like the ascidians. The Indian Express underscored the global stakes, citing projections that melanoma deaths could rise to 96,000 annually by 2040 if new treatments are not developed.
What’s Next for the Research?
What’s Next for the Research?
The next phase involves understanding how the bacterium interacts with its host and how the compound is naturally produced. "This research is important both environmentally and medically," Baker said. Collaborations with the Desert Research Institute and Scripps Institution of Oceanography will focus on synthetic replication and toxicity testing. While no timeline for human trials exists, the discovery has drawn attention for its potential to address a major unmet medical need.
The Broader Implications
The finding aligns with growing interest in extremophiles for medical breakthroughs. "We are learning how organisms use symbiosis to survive in extreme conditions, which is still largely unknown in cold-water ecosystems like Antarctica," Baker noted. However, researchers caution that turning the compound into a drug will require years of testing. "Understanding the source and function of this compound is critical if we hope to develop it into a drug," he added.
The global melanoma burden remains severe, with 57,000 deaths annually and projections of 96,000 by 2040. The Antarctic sea squirt’s bacterium offers a rare example of a naturally occurring compound with both medical promise and ecological uniqueness. As the research progresses, its success could redefine approaches to cancer treatment and highlight the untapped potential of Earth’s most remote environments.
"Scientists believe continued exploration of these extreme environments could reveal new compounds capable of treating diseases that remain difficult to cure today," the Indian Express reported. For now, the team remains focused on the lab work, with Baker acknowledging the "long pathway" but expressing optimism. "You need hundreds of milligrams to grams of this metabolite," he said. "From a basketball size collection of ascidians we might get one-thousandth of that."
The research underscores the intersection of environmental science and medicine, with Antarctica’s unique ecosystem providing a critical resource. As the team works to replicate the compound synthetically, the world watches for the next steps in what could be a transformative medical discovery.
<a href="https://www.theguardian.com/science/2026/jun/29/sea-s
Find more reporting in our Health section.
